BR112014018179B1 - Vetor de expressão viral, partícula viral, uso dos mesmos, composição, e método in vitro para expressão de um polipeptídeo heterólogo em uma célula - Google Patents
Vetor de expressão viral, partícula viral, uso dos mesmos, composição, e método in vitro para expressão de um polipeptídeo heterólogo em uma célula Download PDFInfo
- Publication number
- BR112014018179B1 BR112014018179B1 BR112014018179-9A BR112014018179A BR112014018179B1 BR 112014018179 B1 BR112014018179 B1 BR 112014018179B1 BR 112014018179 A BR112014018179 A BR 112014018179A BR 112014018179 B1 BR112014018179 B1 BR 112014018179B1
- Authority
- BR
- Brazil
- Prior art keywords
- piv5
- virus
- mice
- gene
- influenza
- Prior art date
Links
- 230000003612 virological effect Effects 0.000 title claims abstract description 62
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 47
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 43
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 43
- 239000013604 expression vector Substances 0.000 title claims abstract description 34
- 238000000034 method Methods 0.000 title claims description 42
- 239000000203 mixture Substances 0.000 title claims description 29
- 239000002245 particle Substances 0.000 title claims description 25
- 238000000338 in vitro Methods 0.000 title claims description 18
- -1 their use Substances 0.000 title description 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 174
- 239000002773 nucleotide Substances 0.000 claims abstract description 74
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 74
- 101710200413 Small hydrophobic protein Proteins 0.000 claims abstract description 68
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims abstract description 21
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims abstract description 20
- 241001559185 Mammalian rubulavirus 5 Species 0.000 claims description 724
- 101710154606 Hemagglutinin Proteins 0.000 claims description 176
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 176
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 176
- 101710176177 Protein A56 Proteins 0.000 claims description 176
- 239000000185 hemagglutinin Substances 0.000 claims description 170
- 230000035772 mutation Effects 0.000 claims description 93
- 230000014509 gene expression Effects 0.000 claims description 80
- 101710188314 Protein V Proteins 0.000 claims description 76
- 108010089430 Phosphoproteins Proteins 0.000 claims description 64
- 102000007982 Phosphoproteins Human genes 0.000 claims description 61
- 206010022000 influenza Diseases 0.000 claims description 60
- 102000004169 proteins and genes Human genes 0.000 claims description 41
- 108020001507 fusion proteins Proteins 0.000 claims description 37
- 241000712431 Influenza A virus Species 0.000 claims description 36
- 102000037865 fusion proteins Human genes 0.000 claims description 36
- 208000037797 influenza A Diseases 0.000 claims description 31
- 101150084044 P gene Proteins 0.000 claims description 22
- 241000252870 H3N2 subtype Species 0.000 claims description 19
- 102100034574 P protein Human genes 0.000 claims description 15
- 101710181008 P protein Proteins 0.000 claims description 14
- 101710177166 Phosphoprotein Proteins 0.000 claims description 14
- 230000006907 apoptotic process Effects 0.000 claims description 14
- 241001353878 Canine parainfluenza virus Species 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 7
- 241000713196 Influenza B virus Species 0.000 claims description 4
- 241000713297 Influenza C virus Species 0.000 claims description 3
- 208000037798 influenza B Diseases 0.000 claims description 3
- 206010064571 Gene mutation Diseases 0.000 claims description 2
- 241001473385 H5N1 subtype Species 0.000 claims description 2
- 108010015724 Prephenate Dehydratase Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 326
- 229960005486 vaccine Drugs 0.000 abstract description 221
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 abstract description 9
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 abstract 2
- 241000699670 Mus sp. Species 0.000 description 353
- 210000004027 cell Anatomy 0.000 description 227
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 135
- 108060004795 Methyltransferase Proteins 0.000 description 128
- 241000282472 Canis lupus familiaris Species 0.000 description 120
- 208000015181 infectious disease Diseases 0.000 description 114
- 241000712461 unidentified influenza virus Species 0.000 description 100
- 238000007918 intramuscular administration Methods 0.000 description 95
- 230000003053 immunization Effects 0.000 description 91
- 238000002649 immunization Methods 0.000 description 90
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 82
- 238000002255 vaccination Methods 0.000 description 81
- 239000002953 phosphate buffered saline Substances 0.000 description 79
- 239000013598 vector Substances 0.000 description 72
- 241001465754 Metazoa Species 0.000 description 70
- 230000036039 immunity Effects 0.000 description 70
- 210000002966 serum Anatomy 0.000 description 70
- 230000004224 protection Effects 0.000 description 67
- 238000003556 assay Methods 0.000 description 58
- 241000711798 Rabies lyssavirus Species 0.000 description 57
- 230000003472 neutralizing effect Effects 0.000 description 56
- 239000000427 antigen Substances 0.000 description 55
- 108091007433 antigens Proteins 0.000 description 55
- 102000036639 antigens Human genes 0.000 description 55
- 238000003780 insertion Methods 0.000 description 53
- 230000037431 insertion Effects 0.000 description 53
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 48
- 231100000518 lethal Toxicity 0.000 description 48
- 230000001665 lethal effect Effects 0.000 description 48
- 241000282412 Homo Species 0.000 description 45
- 210000004072 lung Anatomy 0.000 description 45
- 108010006232 Neuraminidase Proteins 0.000 description 44
- 102000005348 Neuraminidase Human genes 0.000 description 43
- 230000028993 immune response Effects 0.000 description 43
- 239000013612 plasmid Substances 0.000 description 41
- 206010037742 Rabies Diseases 0.000 description 40
- 241000282414 Homo sapiens Species 0.000 description 39
- 230000001681 protective effect Effects 0.000 description 39
- 238000011081 inoculation Methods 0.000 description 38
- 238000002965 ELISA Methods 0.000 description 34
- 239000012091 fetal bovine serum Substances 0.000 description 34
- 230000004580 weight loss Effects 0.000 description 33
- 108060003393 Granulin Proteins 0.000 description 32
- 230000012010 growth Effects 0.000 description 32
- 235000018102 proteins Nutrition 0.000 description 32
- 230000004083 survival effect Effects 0.000 description 31
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 30
- 229960003127 rabies vaccine Drugs 0.000 description 30
- 238000012360 testing method Methods 0.000 description 29
- 238000010790 dilution Methods 0.000 description 25
- 239000012895 dilution Substances 0.000 description 25
- 101150039660 HA gene Proteins 0.000 description 24
- 101150118742 NP gene Proteins 0.000 description 24
- 230000004044 response Effects 0.000 description 24
- 229940125575 vaccine candidate Drugs 0.000 description 24
- 238000011161 development Methods 0.000 description 23
- 230000018109 developmental process Effects 0.000 description 23
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 22
- 239000013603 viral vector Substances 0.000 description 21
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 20
- 230000005875 antibody response Effects 0.000 description 20
- 230000010076 replication Effects 0.000 description 20
- 210000003501 vero cell Anatomy 0.000 description 20
- 210000002845 virion Anatomy 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 239000000872 buffer Substances 0.000 description 19
- 230000005867 T cell response Effects 0.000 description 18
- 230000001717 pathogenic effect Effects 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 17
- 238000001514 detection method Methods 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 229940098773 bovine serum albumin Drugs 0.000 description 16
- 230000001404 mediated effect Effects 0.000 description 16
- 239000006228 supernatant Substances 0.000 description 16
- 241000287828 Gallus gallus Species 0.000 description 15
- 241000711386 Mumps virus Species 0.000 description 15
- 241000282339 Mustela Species 0.000 description 15
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 238000001727 in vivo Methods 0.000 description 15
- 206010064097 avian influenza Diseases 0.000 description 14
- 238000010166 immunofluorescence Methods 0.000 description 14
- 230000002516 postimmunization Effects 0.000 description 14
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 241000283707 Capra Species 0.000 description 13
- 101150107578 SH gene Proteins 0.000 description 13
- 229930006000 Sucrose Natural products 0.000 description 13
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 13
- 230000024932 T cell mediated immunity Effects 0.000 description 13
- 230000008901 benefit Effects 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 235000013601 eggs Nutrition 0.000 description 13
- 229960003971 influenza vaccine Drugs 0.000 description 13
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 13
- 239000005720 sucrose Substances 0.000 description 13
- 238000001262 western blot Methods 0.000 description 13
- 238000012217 deletion Methods 0.000 description 12
- 230000037430 deletion Effects 0.000 description 12
- 241001493065 dsRNA viruses Species 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 238000013518 transcription Methods 0.000 description 12
- 230000035897 transcription Effects 0.000 description 12
- 241000282465 Canis Species 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 235000013330 chicken meat Nutrition 0.000 description 11
- 230000002458 infectious effect Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 230000009385 viral infection Effects 0.000 description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 230000005847 immunogenicity Effects 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 238000003757 reverse transcription PCR Methods 0.000 description 10
- 238000011725 BALB/c mouse Methods 0.000 description 9
- 101150034814 F gene Proteins 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 9
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 241000700618 Vaccinia virus Species 0.000 description 9
- 108010067390 Viral Proteins Proteins 0.000 description 9
- 238000010171 animal model Methods 0.000 description 9
- 239000005090 green fluorescent protein Substances 0.000 description 9
- 230000000977 initiatory effect Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 238000013207 serial dilution Methods 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 206010011224 Cough Diseases 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- 101150008820 HN gene Proteins 0.000 description 8
- 241000725303 Human immunodeficiency virus Species 0.000 description 8
- 230000002238 attenuated effect Effects 0.000 description 8
- 230000000903 blocking effect Effects 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 230000002163 immunogen Effects 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 230000000644 propagated effect Effects 0.000 description 8
- 229960005322 streptomycin Drugs 0.000 description 8
- 241000701161 unidentified adenovirus Species 0.000 description 8
- 238000011144 upstream manufacturing Methods 0.000 description 8
- 230000029812 viral genome replication Effects 0.000 description 8
- 241000711404 Avian avulavirus 1 Species 0.000 description 7
- 101150011571 BSL2 gene Proteins 0.000 description 7
- 241000712083 Canine morbillivirus Species 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 101150082239 G gene Proteins 0.000 description 7
- 208000002979 Influenza in Birds Diseases 0.000 description 7
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 7
- 241001263478 Norovirus Species 0.000 description 7
- 230000001857 anti-mycotic effect Effects 0.000 description 7
- 239000002543 antimycotic Substances 0.000 description 7
- 230000003115 biocidal effect Effects 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 230000034994 death Effects 0.000 description 7
- 231100000517 death Toxicity 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 238000012809 post-inoculation Methods 0.000 description 7
- 238000010839 reverse transcription Methods 0.000 description 7
- 210000004988 splenocyte Anatomy 0.000 description 7
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 6
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 6
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 108090000288 Glycoproteins Proteins 0.000 description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 6
- 208000005647 Mumps Diseases 0.000 description 6
- 229930182555 Penicillin Natural products 0.000 description 6
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 6
- 241000202347 Porcine circovirus Species 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 238000011053 TCID50 method Methods 0.000 description 6
- 108020000999 Viral RNA Proteins 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 230000000120 cytopathologic effect Effects 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 230000035931 haemagglutination Effects 0.000 description 6
- 230000012447 hatching Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 231100000636 lethal dose Toxicity 0.000 description 6
- 208000010805 mumps infectious disease Diseases 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 229940049954 penicillin Drugs 0.000 description 6
- 244000144977 poultry Species 0.000 description 6
- 235000013594 poultry meat Nutrition 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 201000010740 swine influenza Diseases 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 101800001467 Envelope glycoprotein E2 Proteins 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 101150062031 L gene Proteins 0.000 description 5
- 241000282341 Mustela putorius furo Species 0.000 description 5
- 101800001271 Surface protein Proteins 0.000 description 5
- 108700005077 Viral Genes Proteins 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 230000009260 cross reactivity Effects 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 238000002296 dynamic light scattering Methods 0.000 description 5
- 210000002257 embryonic structure Anatomy 0.000 description 5
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000002054 inoculum Substances 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- LHEJDBBHZGISGW-UHFFFAOYSA-N 5-fluoro-3-(3-oxo-1h-2-benzofuran-1-yl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(F)=CNC(=O)N1C1C2=CC=CC=C2C(=O)O1 LHEJDBBHZGISGW-UHFFFAOYSA-N 0.000 description 4
- 101100272788 Arabidopsis thaliana BSL3 gene Proteins 0.000 description 4
- 241001519465 Avian metapneumovirus Species 0.000 description 4
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 4
- 241000893570 Hendra henipavirus Species 0.000 description 4
- 229940124873 Influenza virus vaccine Drugs 0.000 description 4
- 241000712079 Measles morbillivirus Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 description 4
- 241000711897 Rinderpest morbillivirus Species 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 4
- 210000000234 capsid Anatomy 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000036755 cellular response Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 229940031551 inactivated vaccine Drugs 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 4
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 4
- 210000005015 mediastinal lymph node Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
- 231100000735 select agent Toxicity 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000711895 Bovine orthopneumovirus Species 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 241001115402 Ebolavirus Species 0.000 description 3
- 238000011510 Elispot assay Methods 0.000 description 3
- 101150105849 H5 gene Proteins 0.000 description 3
- 241000342334 Human metapneumovirus Species 0.000 description 3
- 241000711920 Human orthopneumovirus Species 0.000 description 3
- 101900222562 Influenza A virus Nucleoprotein Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 3
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 3
- 241000526636 Nipah henipavirus Species 0.000 description 3
- 241001617329 Norovirus isolates Species 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 101900083372 Rabies virus Glycoprotein Proteins 0.000 description 3
- 108010081734 Ribonucleoproteins Proteins 0.000 description 3
- 102000004389 Ribonucleoproteins Human genes 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 101150037646 VP gene Proteins 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000002155 anti-virotic effect Effects 0.000 description 3
- 230000030741 antigen processing and presentation Effects 0.000 description 3
- 230000005775 apoptotic pathway Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000001627 detrimental effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000028996 humoral immune response Effects 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000021633 leukocyte mediated immunity Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 229960001226 live attenuated influenza Drugs 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000004264 monolayer culture Methods 0.000 description 3
- FRZJZRVZZNTMAW-UHFFFAOYSA-N n,n-diethyl-3-(hydroxymethyl)benzamide Chemical compound CCN(CC)C(=O)C1=CC=CC(CO)=C1 FRZJZRVZZNTMAW-UHFFFAOYSA-N 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000005180 public health Effects 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 229940126580 vector vaccine Drugs 0.000 description 3
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 206010001935 American trypanosomiasis Diseases 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 241001466804 Carnivora Species 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 241000288673 Chiroptera Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 238000011537 Coomassie blue staining Methods 0.000 description 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 241000886677 Duck adenovirus 1 Species 0.000 description 2
- 241000714165 Feline leukemia virus Species 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 101150066002 GFP gene Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 206010069767 H1N1 influenza Diseases 0.000 description 2
- 229940033330 HIV vaccine Drugs 0.000 description 2
- 241001559187 Human rubulavirus 2 Species 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 241000711450 Infectious bronchitis virus Species 0.000 description 2
- 101100028758 Influenza A virus (strain A/Swine/Wisconsin/1/1967 H1N1) PB1-F2 gene Proteins 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- 108091029795 Intergenic region Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 235000019687 Lamb Nutrition 0.000 description 2
- 101710169105 Minor spike protein Proteins 0.000 description 2
- 101710081079 Minor spike protein H Proteins 0.000 description 2
- 208000007696 Multicystic Dysplastic Kidney Diseases 0.000 description 2
- 101150080862 NA gene Proteins 0.000 description 2
- 208000010359 Newcastle Disease Diseases 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 101150103639 PB1 gene Proteins 0.000 description 2
- 241000711504 Paramyxoviridae Species 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 240000005578 Rivina humilis Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 241000223109 Trypanosoma cruzi Species 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 208000035472 Zoonoses Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 229940031567 attenuated vaccine Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000005101 cell tropism Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 230000007236 host immunity Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- 230000000521 hyperimmunizing effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 238000012768 mass vaccination Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 230000016379 mucosal immune response Effects 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 229940126578 oral vaccine Drugs 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000008823 permeabilization Effects 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229960000380 propiolactone Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229950004616 tribromoethanol Drugs 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000007444 viral RNA synthesis Effects 0.000 description 2
- 229940023147 viral vector vaccine Drugs 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 206010048282 zoonosis Diseases 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- GFWBKUDRXMQSFD-FJXQXJEOSA-M 3-aminopropanoyl-[(1s)-1-carboxy-2-(1h-imidazol-5-yl)ethyl]azanide;zinc Chemical compound [Zn].NCCC(=O)[N-][C@H](C(O)=O)CC1=CN=CN1 GFWBKUDRXMQSFD-FJXQXJEOSA-M 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000405758 Betapartitivirus Species 0.000 description 1
- 241001279357 Canine calicivirus Species 0.000 description 1
- 241000701157 Canine mastadenovirus A Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000014085 Chronic respiratory disease Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 208000000655 Distemper Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 241000714201 Feline calicivirus Species 0.000 description 1
- 241000701047 Gallid alphaherpesvirus 2 Species 0.000 description 1
- 101150111468 H3 gene Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101000588045 Homo sapiens Kunitz-type protease inhibitor 1 Proteins 0.000 description 1
- 101000661807 Homo sapiens Suppressor of tumorigenicity 14 protein Proteins 0.000 description 1
- 241000712003 Human respirovirus 3 Species 0.000 description 1
- 241001559186 Human rubulavirus 4 Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000134304 Influenza A virus H3N2 Species 0.000 description 1
- 101900159346 Influenza A virus Hemagglutinin Proteins 0.000 description 1
- 101900330348 Influenza A virus Matrix protein 1 Proteins 0.000 description 1
- 241000371980 Influenza B virus (B/Shanghai/361/2002) Species 0.000 description 1
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 101710180643 Leishmanolysin Proteins 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 241000711828 Lyssavirus Species 0.000 description 1
- 101150109178 M1 gene Proteins 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 241000266847 Mephitidae Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000711513 Mononegavirales Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 101000985498 Mus musculus Hermansky-Pudlak syndrome 4 protein homolog Proteins 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 101000930679 Nipah virus Fusion glycoprotein F0 Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 241000272458 Numididae Species 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 208000009620 Orthomyxoviridae Infections Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 241000702437 Parvovirus H3 Species 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 description 1
- 102400001018 Proadrenomedullin N-20 terminal peptide Human genes 0.000 description 1
- 241000282335 Procyon Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 101000933967 Pseudomonas phage KPP25 Major capsid protein Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 238000010357 RNA editing Methods 0.000 description 1
- 230000026279 RNA modification Effects 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 206010051497 Rhinotracheitis Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241001533467 Rubulavirus Species 0.000 description 1
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 208000003028 Stuttering Diseases 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 241000711955 Turkey rhinotracheitis virus Species 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
- 229960005054 acepromazine Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 108010045649 agarase Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 244000037640 animal pathogen Species 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000014058 canine distemper Diseases 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000003555 cloaca Anatomy 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 108010078428 env Gene Products Proteins 0.000 description 1
- 244000309457 enveloped RNA virus Species 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 230000034725 extrinsic apoptotic signaling pathway Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 101150118163 h gene Proteins 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000007235 immunity generation Effects 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000037799 influenza C Diseases 0.000 description 1
- 108700010900 influenza virus proteins Proteins 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 230000034727 intrinsic apoptotic signaling pathway Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 230000000174 oncolytic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 229940056457 promace Drugs 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229940036105 rabies immunoglobulin Drugs 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000017960 syncytium formation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000001944 turbinate Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009447 viral pathogenesis Effects 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 229940126581 whole-virion vaccine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18721—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18732—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18741—Use of virus, viral particle or viral elements as a vector
- C12N2760/18743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18771—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261590056P | 2012-01-24 | 2012-01-24 | |
| US201261590070P | 2012-01-24 | 2012-01-24 | |
| US61/590,056 | 2012-01-24 | ||
| US61/590,070 | 2012-01-24 | ||
| US201261683810P | 2012-08-16 | 2012-08-16 | |
| US61/683,810 | 2012-08-16 | ||
| PCT/US2013/022962 WO2013112720A1 (en) | 2012-01-24 | 2013-01-24 | Parainfluenza virus 5 based vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014018179A2 BR112014018179A2 (pt) | 2017-07-04 |
| BR112014018179B1 true BR112014018179B1 (pt) | 2022-04-12 |
Family
ID=48873896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014018179-9A BR112014018179B1 (pt) | 2012-01-24 | 2013-01-24 | Vetor de expressão viral, partícula viral, uso dos mesmos, composição, e método in vitro para expressão de um polipeptídeo heterólogo em uma célula |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US9505807B2 (enExample) |
| EP (2) | EP2806891B1 (enExample) |
| JP (3) | JP6228136B2 (enExample) |
| CN (2) | CN104093422B (enExample) |
| AU (1) | AU2013212097B2 (enExample) |
| BR (1) | BR112014018179B1 (enExample) |
| CA (2) | CA2860388C (enExample) |
| ES (1) | ES2728248T3 (enExample) |
| MX (1) | MX359638B (enExample) |
| MY (1) | MY173638A (enExample) |
| PH (1) | PH12014501255B1 (enExample) |
| PT (1) | PT2806891T (enExample) |
| WO (2) | WO2013112690A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3123276A1 (en) | 2011-02-25 | 2012-08-30 | University Of Georgia Research Foundation, Inc. | Recombinant mumps virus vaccine |
| AU2013212097B2 (en) | 2012-01-24 | 2017-01-12 | University Of Georgia Research Foundation, Inc. | Parainfluenza virus 5 based vaccines |
| KR101577397B1 (ko) * | 2014-01-15 | 2015-12-28 | 경북대학교 산학협력단 | 신규한 돼지 파라인플루엔자 바이러스 5(pPIV5), 이를 포함하는 백신 조성물 및 이를 이용한 돼지 파라인플루엔자 바이러스 검정 키트 |
| EP3288595B1 (en) * | 2015-04-28 | 2020-12-30 | The University Of Georgia Research Foundation, Inc. | Piv5-based amplifying virus-like particles |
| US20180339038A1 (en) * | 2015-06-12 | 2018-11-29 | Mie University | Human parainfluenza virus type 2 vector and vaccine |
| IL270876B2 (en) * | 2017-05-25 | 2024-06-01 | Univ Central Florida Res Found Inc | Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells |
| RU2681473C1 (ru) * | 2018-01-16 | 2019-03-06 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный аграрный университет имени И.Т. Трубилина" | Тест-система для обнаружения генома вируса парагриппа 3 типа у крупного рогатого скота с помощью мультиплексной полимеразной цепной реакции с флуоресцентной детекцией в режиме реального времени |
| GB201816873D0 (en) * | 2018-10-17 | 2018-11-28 | Imperial Innovations Ltd | Fusion protein |
| WO2020092207A1 (en) * | 2018-10-28 | 2020-05-07 | University Of Georgia Research Foundation | Broadly reactive immunogens of influenza virus, compositions, and methods of use thereof |
| CL2018003869A1 (es) * | 2018-12-28 | 2021-01-15 | Univ Pontificia Catolica Chile | Anticuerpos monoclonales específicos para la proteína quimérica l del virus de la parainfluenza humana (piv), secuencias nucleotídicas; método y kit de diagnóstico de infección producida por piv |
| CA3196157A1 (en) * | 2020-09-21 | 2022-03-24 | University Of Georgia Research Foundation, Inc. | Piv5-based covid-19 vaccine |
| US20240102912A1 (en) * | 2020-11-09 | 2024-03-28 | Thrive Bioscience, Inc. | Plaque counting assay method |
| CN113005149A (zh) * | 2021-03-26 | 2021-06-22 | 中国农业大学 | 一种表达冠状病毒受体结合域串联二聚体的重组副流感病毒5型载体 |
| AU2022332107A1 (en) * | 2021-08-26 | 2024-03-14 | University Of Georgia Research Foundation, Inc. | J paramyxovirus vaccines |
| GB202209861D0 (en) * | 2022-07-05 | 2022-08-17 | Univ Court Univ St Andrews | Viral vectors |
| AU2023372210A1 (en) * | 2022-11-04 | 2025-05-29 | Blue Lake Biotechnology, Inc. | Recombinant rsv vaccine: methods of making and using the same |
| JP2026504603A (ja) * | 2023-02-06 | 2026-02-05 | サイアンバック エルエルシー | 修飾ｐｉｖ５ワクチンベクター：作製方法及び使用方法 |
| CN116270766A (zh) * | 2023-02-23 | 2023-06-23 | 天津理工大学 | 一种副流感病毒5型作为溶瘤病毒在抗肿瘤中的应用 |
| CN117625560B (zh) * | 2023-11-03 | 2025-09-16 | 中国农业大学 | 一种重组病毒rPIV5-H3及其制备方法、应用和疫苗 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6638762B1 (en) | 1994-11-28 | 2003-10-28 | Genetic Therapy, Inc. | Tissue-vectors specific replication and gene expression |
| CA2160038A1 (en) * | 1995-07-14 | 1997-01-15 | Biosignal Inc. | Methods of screening compounds for their pharmacological relevance based on downregulation of recombinant receptors |
| JP2000509280A (ja) | 1996-05-01 | 2000-07-25 | アメリカ合衆国 | 組換えｄｎａ由来ヌクレオキャプシドタンパク質を用いるウイルストランスフェクタントの作製 |
| US6410023B1 (en) * | 1997-05-23 | 2002-06-25 | United States Of America | Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene |
| US5962274A (en) | 1998-03-13 | 1999-10-05 | Wake Forest University | Viral vector directed to predetermined target cells |
| CN102766605A (zh) * | 1999-12-10 | 2012-11-07 | 由卫生与公众服务部代表的美利坚合众国政府 | 重组副流感病毒(piv)作为载体提供保护对抗piv及其他人类病原体引起的感染和疾病的用途 |
| US6764685B1 (en) | 2000-03-21 | 2004-07-20 | Medimmune Vaccines, Inc. | Recombinant parainfluenza virus expression systems and vaccines |
| JP2002153278A (ja) | 2000-11-22 | 2002-05-28 | Hisamitsu Pharmaceut Co Inc | ウイルスベクターの製造に用いられる細胞、その製法およびその細胞を用いたウイルスベクターの製造方法 |
| AU2002327755A1 (en) | 2001-09-28 | 2003-04-14 | Rush-Presbyterian-St. Luke's Medical Center | Paramyxoviruses as gene transfer vectors to lung cells |
| WO2005005645A1 (en) | 2003-06-13 | 2005-01-20 | Apath, Llc | Negative strand rna virus replicon |
| DK2540312T3 (en) | 2007-07-19 | 2015-07-20 | Novavax Inc | Chimeric avian influenza VLPs |
| US20090208495A1 (en) | 2008-02-14 | 2009-08-20 | Bayer Schering Pharma Ag | Anti-tumor effective paramyxovirus |
| FR2938840B1 (fr) | 2008-11-21 | 2010-12-17 | Centre Nat Rech Scient | Proteines mutantes de la proteine f de piv-5 et de piv-2 |
| US10227569B2 (en) | 2011-04-12 | 2019-03-12 | Emory University | Respiratory syncytial virus expression vectors |
| AU2013212097B2 (en) | 2012-01-24 | 2017-01-12 | University Of Georgia Research Foundation, Inc. | Parainfluenza virus 5 based vaccines |
-
2013
- 2013-01-24 AU AU2013212097A patent/AU2013212097B2/en active Active
- 2013-01-24 PT PT13741216T patent/PT2806891T/pt unknown
- 2013-01-24 MX MX2014008557A patent/MX359638B/es active IP Right Grant
- 2013-01-24 US US14/374,061 patent/US9505807B2/en active Active
- 2013-01-24 EP EP13741216.9A patent/EP2806891B1/en active Active
- 2013-01-24 WO PCT/US2013/022898 patent/WO2013112690A1/en not_active Ceased
- 2013-01-24 JP JP2014554824A patent/JP6228136B2/ja active Active
- 2013-01-24 WO PCT/US2013/022962 patent/WO2013112720A1/en not_active Ceased
- 2013-01-24 CN CN201380006495.2A patent/CN104093422B/zh active Active
- 2013-01-24 CA CA2860388A patent/CA2860388C/en active Active
- 2013-01-24 CA CA3128591A patent/CA3128591A1/en active Pending
- 2013-01-24 EP EP19165071.2A patent/EP3536341A1/en active Pending
- 2013-01-24 ES ES13741216T patent/ES2728248T3/es active Active
- 2013-01-24 MY MYPI2014702016A patent/MY173638A/en unknown
- 2013-01-24 US US14/374,070 patent/US9732358B2/en active Active
- 2013-01-24 BR BR112014018179-9A patent/BR112014018179B1/pt active IP Right Grant
- 2013-01-24 CN CN201810061733.4A patent/CN108130345A/zh active Pending
-
2014
- 2014-06-04 PH PH12014501255A patent/PH12014501255B1/en unknown
-
2016
- 2016-10-18 US US15/296,346 patent/US10752916B2/en active Active
-
2017
- 2017-06-30 US US15/638,946 patent/US10329585B2/en active Active
- 2017-10-12 JP JP2017198111A patent/JP2018050624A/ja active Pending
-
2019
- 2019-05-24 US US16/421,837 patent/US20190284578A1/en not_active Abandoned
- 2019-09-18 JP JP2019168928A patent/JP6900437B2/ja active Active
-
2020
- 2020-08-10 US US16/989,038 patent/US11542527B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11542527B2 (en) | Parainfluenza virus 5 based vaccines | |
| US11180737B2 (en) | Generation of infectious influenza viruses from virus-like particles | |
| ES2655051T3 (es) | Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas | |
| BR112014006694A2 (pt) | vacinas contra o vírus influenza e usos dessas | |
| US20230310583A1 (en) | Recombinant newcastle disease virus expressing sars-cov-2 spike protein and uses thereof | |
| US12391957B2 (en) | Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease | |
| CN101643721A (zh) | 广谱安全型动物用抗甲型流感病毒疫苗 | |
| US20250041402A1 (en) | Recombinant newcastle disease virus expressing spike protein of sars-cov-2 delta variant and uses thereof | |
| Le et al. | Induction of influenza-specific mucosal immunity by an attenuated recombinant Sendai virus | |
| US20240199705A1 (en) | Chimeric newcastle disease virus expressing apmv hn and f proteins | |
| KR101908905B1 (ko) | 인플루엔자 바이러스의 h9 및 h5의 다중 아형에 대한 교차 면역반응을 형성하는 신규한 재조합 인플루엔자 바이러스 및 이를 포함하는 백신 | |
| US20250250304A1 (en) | Recombinant newcastle disease virus expressing lassa virus gp or np, and uses thereof | |
| US20250186578A1 (en) | Recombinant newcastle disease viruses and immunogenic compositions for use in preventing covid-19 | |
| Goff | Toward broadly protective influenza virus vaccines using novel adjuvants, antigens and recombinant viruses | |
| Baker | The Packaging Signals of Influenza A and B Viruses Contribute to Their Speciation and Can Be Manipulated for Novel Vaccine Development |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.21 NA RPI NO 2608 DE 29/12/2020 POR TER SIDO INDEVIDA. |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/01/2013, OBSERVADAS AS CONDICOES LEGAIS. |